FP10 and the Innovation Act: What Coordinators Need to Know
The European Innovation Act will fundamentally transform how the 10th EU Framework Programme for Research and Innovation (FP10) operates when it launches. The Act aims to create cross-sectoral legal frameworks that remove barriers for bringing innovative ideas to market across all sectors, directly impacting how you structure consortia and plan commercialisation strategies. According to the European Commission's Innovation Act strategy documents, this legislation will address commercialisation of research results, industry-academia collaboration, and access to markets, finance, talent and infrastructures.
FP10 will run from 2028-2034 with significant structural changes driven by the Innovation Act's focus on market deployment. Many coordinators find that current Horizon Europe projects struggle with the commercialisation gap — the European Commission notes that Europe produces high-quality research but faces challenges in transforming research into successful market products. The Innovation Act specifically targets this challenge by creating more coordinated regulatory, policy and investment frameworks.
What Is the European Innovation Act and How Will It Impact FP10?
The European Innovation Act is a comprehensive legislative framework that the European Commission plans to adopt in 2026, as announced in the EU Startup and Scaleup Strategy and the Competitiveness Compass for the EU. The Act will create cross-sectoral legal conditions to remove barriers for bringing innovative ideas to market across all sectors.
The Innovation Act addresses several critical areas that directly affect project management in FP10. It focuses on commercialisation of research results, collaboration between industry and academia, access to markets, finance, talent and infrastructures. The legislation will also create more coordinated regulatory, policy and investment frameworks aimed at bringing innovative solutions to market across the EU Single Market.
For project coordinators, this means FP10 projects will need stronger commercialisation strategies from the proposal stage. The Act recognises that Europe's underinvestment in commercialisation affects all sectors, requiring more agile innovation pathways that pool EU, national and private investments. According to the European Commission's Innovation Act framework, Europe must overcome the innovation gap to boost competitiveness and growth.
How Will FP10 Structure Change Under the Innovation Act?
FP10 will maintain its independence as a research and innovation programme, but with enhanced integration across EU policies. The European Parliament's Committee on Industry, Research, and Energy (ITRE) has approved an initiative report advocating for an independent FP10 with a significantly higher budget, emphasising simplified administrative processes and more support for disruptive research.
Stakeholder organisations propose an ambitious budget of at least EUR 200 billion for FP10, ring-fenced for R&D activities according to the Netherlands Federation of University Medical Centres position paper. This represents a substantial increase from the current Horizon Europe programme.
The Innovation Act will drive better integration between FP10 and other EU programmes, including Cohesion Funds and Digital Europe Programme. This coordination aims to maximise innovation support impact across Europe, creating synergies that current programmes struggle to achieve. Project coordinators should expect more streamlined application processes but with stronger requirements for demonstrating market potential and commercialisation pathways.
What Are the Key Commercialisation Requirements for FP10 Projects?
The Innovation Act will introduce new commercialisation requirements that fundamentally change how you approach project planning and consortium building. Projects will need to demonstrate clear pathways from research to market deployment, with stronger industry participation throughout the innovation process.
The Act emphasises intellectual property rights exploitation, standardisation and certification of innovative solutions as key success factors. This means your consortia will need partners with commercialisation expertise, not just research excellence. The European Federation of Pharmaceutical Industries and Associations recommends that FP10 should cover the whole spectrum of research, including late-stage development.
The European Commission identifies that innovative companies face difficulties accessing and growing in the EU market, which the Innovation Act will address through more innovation-friendly public and private procurement. This creates opportunities for FP10 projects to engage with procurement processes as validation and market entry strategies. Projects should plan for regulatory sandbox participation, where innovations can be developed and tested safely before full market deployment.
A common challenge is that current Horizon Europe funding often stops before commercial validation. The Innovation Act will encourage instruments that bridge this gap, potentially including innovation procurement, risk-sharing mechanisms, and direct market deployment support within project budgets.
How Should Coordinators Prepare Consortia for FP10 Changes?
Your consortium composition will need to evolve significantly for FP10 success under the Innovation Act framework. Industry participation must move beyond traditional advisory roles to active partnership in defining research directions and commercialisation strategies. The Catalan Government's position paper emphasises greater attractiveness to SMEs and strengthening horizontal European Research Area activities.
Start building relationships with technology transfer offices, venture capital firms, and commercialisation specialists now. FP10 projects will require demonstrated access to scaling resources, market intelligence, and regulatory expertise. Your work package structure should include explicit commercialisation tasks with dedicated budgets and qualified partners.
The Innovation Act's focus on cross-sectoral solutions means your consortia should span multiple industries where appropriate. For example, digital health innovations should include healthcare providers, technology companies, regulatory bodies, and patient organisations. This cross-sectoral approach aligns with the Act's goal of removing barriers across all sectors simultaneously.
Excellence remains crucial, but geographical balance requirements may be relaxed to include the best global experts, as recommended by pharmaceutical industry stakeholders through the European Federation of Pharmaceutical Industries and Associations. Plan for international collaboration within the consortium, particularly with associated countries and strategic partners who bring unique commercialisation capabilities.
What Financial and Administrative Changes Should Teams Expect?
Administrative simplification is a key priority for FP10, building on lessons learned from Horizon Europe's implementation challenges. The Innovation Act will drive streamlined processes, but with enhanced requirements for commercial impact demonstration and market readiness assessment.
Expect new financial instruments that bridge the funding gap between research and market deployment. The Act proposes using intellectual property rights as collateral for additional financing routes, which could affect how you structure project budgets and risk management. Projects may need to demonstrate IP management strategies and commercialisation revenue projections as part of financial planning.
The emphasis on large-scale, capital-intensive strategic technologies suggests FP10 will favour bigger projects with longer timelines and higher budgets. However, this comes with increased accountability for commercial outcomes and market impact. Your financial reporting will likely include commercialisation milestones, market penetration metrics, and technology readiness level progression.
Despite the Commission's promises of streamlined processes, coordinators should prepare for enhanced scrutiny of commercial potential. The Innovation Act aims to address coordination delays through better integration between EU institutions and member state agencies, but early FP10 projects should plan for transition period adjustments.
How Will International Collaboration Change Under the Innovation Act?
The Innovation Act will reshape international collaboration in FP10, balancing strategic autonomy with global excellence. The UK government's position paper emphasises continued strong collaboration despite Brexit, highlighting the importance of maintaining research partnerships for global competitiveness.
Associated countries will play enhanced roles in FP10, particularly in commercialisation and market access activities. The Act's focus on removing market barriers extends to international trade relationships, creating opportunities for projects that demonstrate global scalability and export potential.
Third-country participation rules may be tightened for sensitive technologies while remaining open for fundamental research. Your consortium should assess technology sensitivity early and plan appropriate international partnership strategies. The Innovation Act emphasises protecting strategic technologies while maintaining openness for collaboration that enhances European competitiveness.
Projects involving artificial intelligence, quantum technologies, and advanced manufacturing may face additional scrutiny for international partnerships. However, the Act also recognises that global collaboration is essential for addressing planetary challenges like climate change and health crises, areas where FP10 is expected to maintain broad international openness.
What Does This Mean for Project Coordinators and Research Teams?
The Innovation Act fundamentally changes what success looks like for FP10 projects. Your role as coordinator expands from managing research activities to orchestrating market deployment strategies and commercial outcomes. This requires new competencies in business development, intellectual property management, and market analysis.
Start developing commercialisation expertise within your organisation now. If your institution lacks technology transfer capabilities, consider partnerships with organisations that specialise in research commercialisation. The MedTech Europe recommendations emphasise strengthening industry participation and public-private partnerships throughout the research process.
Your project proposals will need detailed market analysis, competitive landscape assessment, and realistic commercialisation timelines. Budget 10-15% of project resources for commercialisation activities, including market research, intellectual property protection, regulatory compliance, and business model development. This represents a significant shift from current Horizon Europe practices where commercialisation often receives minimal attention.
The Innovation Act creates opportunities for follow-on funding that bridges research and market deployment. Plan your projects with clear exit strategies that position results for additional support through national innovation programmes, private investment, or procurement contracts. Your final reports will need to demonstrate not just scientific achievement but market readiness and commercial potential.
In practice, this means creating project advisory boards that include commercial partners, developing intellectual property strategies before research begins, and maintaining ongoing market intelligence throughout project execution. The most successful FP10 coordinators will be those who integrate commercial thinking into every aspect of project management.
The Innovation Act represents a fundamental evolution in EU research policy, transforming FP10 from a research funding programme into a comprehensive innovation ecosystem. By understanding these changes and preparing accordingly, your consortia can position themselves for success in Europe's next phase of research and innovation funding.
Frequently Asked Questions
When will the European Innovation Act be adopted and how will it affect FP10?
The European Commission plans to adopt the European Innovation Act in 2026, as announced in the EU Startup and Scaleup Strategy. The Act will create cross-sectoral legal frameworks that remove commercialisation barriers, directly shaping FP10's structure and requiring stronger industry participation and market deployment strategies in all projects.
What budget is proposed for FP10 and how does it compare to Horizon Europe?
Stakeholder organisations propose at least EUR 200 billion for FP10 according to the Netherlands Federation of University Medical Centres position paper, representing a substantial increase from the current Horizon Europe programme. The European Parliament's ITRE Committee supports this ambitious increase, emphasising the need for ring-fenced R&D funding to support enhanced commercialisation activities.
How will consortium composition need to change for FP10 success?
FP10 consortia will require active industry participation beyond advisory roles, including technology transfer offices, commercialisation specialists, and market deployment partners. Projects must demonstrate clear pathways from research to market, with 10-15% of budgets allocated to commercialisation activities including IP protection and business model development.
Will FP10 maintain international collaboration opportunities?
FP10 will balance strategic autonomy with global excellence, maintaining openness for fundamental research while potentially tightening rules for sensitive technologies like AI and quantum computing. Associated countries will have enhanced roles in commercialisation, and the programme will favour partnerships that demonstrate global scalability and export potential.
What new competencies will project coordinators need for FP10?
Coordinators will need expertise in business development, intellectual property management, and market analysis beyond traditional research management. Success requires orchestrating market deployment strategies, managing commercial outcomes, and creating project advisory boards that include commercial partners throughout the innovation process.
